Biochemical and Kinetic Study for the Partial Purified Thioredoxin Reductase from Healthy Human Serum
Article Sidebar
Main Article Content
Abstract
The research included the separation of thioredoxin reductase (TrxR) from human blood serum using different biochemical techniques. Two proteinous peaks had been isolated by gel filtration using sephadex)G-50) and three proteinous peaks isolated from sephadex (G-100) that produced by ammonium sulphate precipitation (65%). The approximately molecular weight of the isolated protein as a source of enzyme using gel filtration chromatography (G-100) was (118059 + 925) Dalton.
The results showed two peaks of enzyme when using ion exchange-type DEAE-cellulose and when using electrophoresis technique type SDS-PAGE indicated the presence of two bands from peak of separation column type sephadex G-100 and one band of each peak, resulting from the ion exchange process with molecular weights of 58231 +490 Dalton.
The results showed that the optimum conditions of purified enzyme from human serum was at (200 µg/ml) of protein as a source of the enzyme using (0.4 mol/l) citric acid-Na2HPO4 buffer solution at pH (7) act for (25) minutes at (40°C). Using Line Weaver-Burk plot, the values of maximum velocity (Vmax) and Michaelis constant (Km) were found to be (0.182 µmol/ min) and (0.013 mol/l) respectively using 5,5-- dithio bis (2-nitrobenzoic acid) (DNTB) as a substrate. Finally, this was, also, involved the study of the effect of some chemicals and drugs on the enzyme activity. The results showed that gundinium - HCl is uncompetitive inhibitor, while bromoacetic acid is noncompetitive inhibitor and zinc sulphate is a competitive inhibitor for the enzyme at different concentrations of inhibitors, but dexathamazone was an activator to the enzyme.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
1- Williams, J.S.. "Chemistry and Biochemistry of
Flavonezymes" (Muller, F., ed). CRC Press. Baco
Raton. 1995; Pp.121,211.
2- Orr, M.D. and Vitols, E..A thioredoxin-
Thioredoxin reductase system from rat tumor.
Biochem. Biophys. Res. Commun.,1967; 29, 264-268.
3- Holmgren, A. Bovine thioredoxin system.
Purification of thioredoxin reductase from calf liver
and thymus and studies of its function in disulfide
reduction. J. Biol. Chem.,1977; 252, 4600-4606.
4- Gladysher, V.N.; Jeang, K.T. and Stadtman, T.C.
Selenocysteine, identified as the penultimate Cterminal
residue in human T-cell thioredoxin
reductase, corresponds to TGA in the human
placental gene. Proc. Natl. Acad. Sci.,1996; 93, 6146
-6151.
5- Gromer, S.; Arscott, L.D.; Williams, C.H.J. and
Schirmer, R.H. Human placenta thioredoxin
Reductase. Isolation of the selenoenzymes, steady
state kinetics and inhibition by therapeutic gold
compounds. J. Biol. Chem., 1998; 273, 20096-20101.
6- Gromer, S. and Gross, J.H. Methylseleninate is a
substrate rather than an inhibitor of mammalian
thioredoxin reductase implication for antitumor
effects of selenium. J. Biol. Chem.,2002; 277: 9701.
7- Hashemy, S.; Ungerstedt, J.; Zahedi Avval, F. and
Holmgren, A. Motexafin gadolinium, a tumorselective
drug targeting thioredoxin reductase and
ribonucleotide reductase. J. Biol. Chem. . 2006; 281
(16): 10691–7.
8-Traber, M. G. and Stevens, J. F. Vitamins C and E:
Beneficial effects from a mechanistic perspective.
Free Radic. Biol. Med.2011; 51(5), 1000-1013.
9- Mustacich, D. and Powis, G.Thioredoxin
reductase. Biochem. 2000;267, 6102.
10- Arner, E.S. and Holmgren, A. The thioredoxin
system in cancer. Semin Caner Biol. 2006; 16(6),
420-6.
11- Maggioli, G.;Piacenza,L.; Carambula, B. and
Carmona, C. Purification characterization and
immunolo calization of a thioredoxin reductase from
adult Fasciola Hepatica. J .Paraitol.,2004; 90(2),
205-211.
12- Schacterle, G. R. and Pollack, R. L. A simplified
method for the quantitative assay of small amount of
protein in biological material. Anal. Biochem.1973;
51, 654-655.
13- Holmgren, A. and Bjornstedt, M. Thioredoxin
and thioredoxin reductase. Methods Enzymol.1995;
252, 199-208.
14- Plummer, T.D. An introduction to practical
biochemistry. 2nd. Ed., McGraw-Hill Book Comp.,
1978; U.K.
15- Luthman, M. and Holmgren, A. Rat liver
thioredoxin and thioredoxin reductase. Purification
and characterization. Biochemistry,1982; 21, 6628.
16- Murray, R. K.; Bender, D. A.; Botham, K. M.;
Kennelly, P. J. and Rodwell, V. W." Harper's
Illustrated Biochemistry". 28 ed. The McGraw-Hill
Companies,2009; Chapter 8.
17- Burtis, C. A.; Ashwood, E. R. and Bruns, D.E.
"Tietz Textbook of Clinical Chemistry and Molecular
Diagnostics". By Saunders, an imprint of Elsevier
Inc. USA. 2012; pp.356, 368.
18- Robyt, F.J. and White, J.B. "Biochemical
Techniques, Theory and Practice", books/cole
publishing company, Monterey, California;2001.
19- Arne´r, E. S.; Zhong, L. A. and Lester, P.
Preparation and assay of mammalian thioredoxin and
thioredoxin reductase. Methods Enzymol.1999; 300,
226–239.
20- Rackham, O.; Sheanwood, A. M.; Thyer,R.;Mc
Namara, E.;Davies,SM.; Callus,BA. and Miranda-
Vizuete, A. Substrate and inhibitor specificities differ
between human cytosolic and mitochondrial
thioredoxin reductase : Implication for development
of specific inhibitors. Radic .Biol. Med.2011; 50(6),
689-99.
21- Hirt, R.P.; Müller, S. and Embley, T.M. The
diversity and evolution of thioredoxin reductase: new
perspectives.Trends Parasitol.2002;18 (7), 302.
22- Bauer, H.; Massey, V.; Arscott, L.D.; Schirmer,
R.H. and Ballou, D.P. The mechanism of high Mr
thioredoxin reductase from Drosophila melanogaster.
J. Biol. Chem.,2003; 278, 33020.
23- Zhong, L.; Elias S. J. A., and Holmgren,
A. Structure and mechanism of mammalian
thioredoxin reductase: The active site is a redoxactive
selenolthiolyselenenylsulfide formed from the
conserved cysteine - selenocysteine sequence. PNAS,
2000; 97 (11), 5854–5859.
24- Gabriela, M.; Lucía, P.; Beatriz C. and Carlos, C.
Purification, characterization, and immunolocalization
of thioredoxin reductase from adult fasciola hepatica. J.
of Parasitolo.2004; 90(2), 205-211.
25- Russel, M. and Model, P. Sequence of
thioredoxin reductase from Escherichia coli. Relation
to other flavoprotein disulfide oxidoreductase, J. Biol.
Chem.,1988; 263, 9015-9019.
26- Chae, H.Z.; Chung, S.J. and Rhee, S.G.
Thioredoxin – dependent peroxide reductase from
yeast. J. Biol. Chem,1994; 269(44), 27670-8.
27- Buettner, C.; Harney, J.W. and Berry, M.J. The
caenorhabditis elegans homologue of thioredoxin
reductase contains a selenocysteine insertion
sequence (SECIS) element that differ from
mammalian SECIS elements but directs
selenocysteine incorporation. J. Biol. Chem.,1999;
274, 21598-21602.
28- Krnajski, Z.; Gilberger, T.W.; Walter, R.D. and
Muller, S. The malaria parasite plasmodium
flaciparum possesses a functioal thioredoxin system.
Molecular and Biochemical parasitology.2001;112
(2), 219-228.
29- Sergey, N.G. and Thressa, C.S. Human
thioredoxin reductase from HeLa cells: selective
alkylation of selenocysteine in the protein inhibits
enzyme activity and reduction with NADPH
influences affinity to heparin. Proc. Natl. Acad.
Sci.,1998; 95, 8520-8525.
30- Xia, L.; Nordman, T.; Olsson, J.M. and
Damdimopoulos, A. The Mammalian Cytosolic
Selenoenzyme Thioredoxin reductase reduce
Ubiquinone. J. Biol. Chem., 2003;278(4), 2141-2146.
31- Larsson, A. Thioredoxin reductase from rat liver.
Eur. J. Biochem.,1973; 35, 346.
32- Harvey, R. A. and Ferrier, D. R. " Lippincott’s
Illustrated Reviews: Biochemistry" 5th ed. Lippincott
Williams and Wilkins, a Wolters Kluwer business,
2014; China. P.20,
33- Oblong, J.E.; Gasdaska, P.Y.; Sherrill, K. and
Powis, G. Purification of human thioredoxin
reductase: properties and characterization by
absorption and circular dichroism spectroscopy.
Biochem.1993; 32, 7271-7277.
34- Tandogan, B. and Ulusu, N.N. Thioredoxin
Reductase. J. Biol and Chem.,2011;39(1),87-92.
35- Ganther, H. Selenium metabolism, selenoproteins
and mechanisms of cancer prevention: complexities
with thioredoxin reductase. Carcinogensis.,1999;
20(9), 1657-1666.
36- Nguyen, P.; Awwad, R.T.; Smart, D.D. and Spitz,
D.R. Thioredoxin reductase as anovel molecular
target for cancer therapy . Cancer Lett.2006; 236,
164-174.
37- Horak, F.; Zieglmayer, P.; Zieglmayer, R.;
Lemell, P.; Yao, R.; Staudinger, H. and Danzig, M. A
placebo-controlled study of the nasal decongestant
effect of phenylephrine and pseudoephedrine in the
Vienna Challenge Chamber". Annals of Allergy,
Asthma and Immunology ,2009;102 (2), 116.
38- Nehlig, A.; Daval, J. L. and Debry, G. Caffeine
and the central nervous system: mechanisms of
action, biochemical, metabolic and psychostimulant
effects. Brain Research Reviews.1992; 17 (2), 139 –
170.
39- Barnes, P.J. and Pauwels, R.A . Theophylline in
the management of a sthma: time for reappraisal. Eur.
Respir J. 1994; 7,579-591.
40- Sagara, I.M.; Ozak, T.; Morioka, E.; Wada, K.;
Hondia, K.; Hori, A. and Matsuya, Y. Induced of
prolonged continous slow wave sleep by blocking
cerebral H1-histamine receptors in rats. Br. J.
Pharmacol. 2012; 165(1), 167-182.
41- You, N.; Tao, K.; Zhao, W.; Bao, P.; Li, R.; You,
H. and Zhang, M. Diphenhydramine modulates
cytokins and induced apoptosis in experimental acute
pancreatitis. Methods Find Exp. Clin. Pharmacol.
2010; 32(5), 3011-8.
42- Aloorkar, N.H. and Bhatia, M.S. Rapidly
disintegrating tabletes of metoclopramide-HCl using
novel chemically modified cellulose. Ars. Pharm.
2011; 52(3), 26-34.
43- Lustar, I.; Friedland, I. R.; Jafri, H.S.; Wubbel,
L.; Ahmad, A.; Trujillo, M.; McCoig, C.C., and
McCraken, G.H. Factors influencing the antiinflammatory
effects of Dexamethasone therapy in
experimental pneumococcal meningitis. J.Antimicrob.
Chemotherapy.,2003; 52, 651-655.
44- Nakamura, H.; Nakamura, K. and Yodoi, J.
Redox regulation of cellular activation. Annu. Rev.
Immunol.1997; 15, 351–369.